Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2022-03-02 00:00:00 ET · period of report 2022-02-28 · accession 0001209191-22-014629 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-02 | 2022-02-28 | KPTI | Frenkel Ran | EVP, Chief Dev. Off | S - Sale | $10.24 | -1,663 | 168.3K | -1.0% | -$17.0K |
| D | 2022-03-02 | 2022-02-28 | KPTI | Frenkel Ran | EVP, Chief Dev. Off | A - Grant | $0.00 | +68.2K | 170.0K | +67% | $0 |
| D | 2022-03-02 | 2022-02-28 | KPTI | Frenkel Ran | EVP, Chief Dev. Off | A - Grant | $0.00 | +90.0K | 90.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-28 | S | D | 1,663 | $10.24 | 168,290 | D | — | — | (F2) This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. (F3) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2022-02-28 | A | A | 68,250 | $0.00 | 169,953 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. |
| 3 | Derivative | Stock Option (right to buy) | 2022-02-28 | A | A | 90,000 | $0.00 | 90,000 | D | $10.33 · — to 2032-02-27 | 90,000 Common Stock | (F4) This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |